HRP20121069T1 - Supstituirani derivati amida kao inhibitori protein kinaze - Google Patents

Supstituirani derivati amida kao inhibitori protein kinaze Download PDF

Info

Publication number
HRP20121069T1
HRP20121069T1 HRP20121069TT HRP20121069T HRP20121069T1 HR P20121069 T1 HRP20121069 T1 HR P20121069T1 HR P20121069T T HRP20121069T T HR P20121069TT HR P20121069 T HRP20121069 T HR P20121069T HR P20121069 T1 HRP20121069 T1 HR P20121069T1
Authority
HR
Croatia
Prior art keywords
phenyl
oxo
methyl
carboxamide
dihydro
Prior art date
Application number
HRP20121069TT
Other languages
English (en)
Inventor
Tae-Seong Kim
David Bauer
Steven Bellon
Alessandro Boezio
Shon Booker
Deborah Choquette
Derin D'amico
Noel D'angelo
Celia Dominguez
Ingrid M. Fellows
Julie Germain
Russel Graceffa
Jean-Cristophe Harmange
Satoko Hirai
Daniel La
Matthew Lee
Longbin Liu
Mark H. Normal
Michele Pothashman
Philip Roveto
Ning Xi
Aaron C. Siegmund
Kevin Yang
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HRP20121069T1 publication Critical patent/HRP20121069T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)

Claims (18)

1. Spoj formule I R-X-W-Y-R1 I njegovi enantiomeri, diastereomeri, farmaceutski prihvatljive soli i N-oksidi, gdje R je [image] gdje Z je izabran od N ili CR7; Z1 je izabran od N ili CR7; W je izabran iz grupe koju čine supstituirani ili nesupstituirani fenil, supstituirani ili nesupstituirani piridil, supstituirani ili nesupstituirani pirimidinil, supstituirani ili nesupstituirani piridazinil i supstituirani ili nesupstituirani pirazinil; X je O; Y je izabran od -NRaC(=O)-(CR3R4)p- i -NRaC(=S)-(CR3R4)p-; Ra je izabran iz grupe koju čine H, alkil, heterociklil, aril, alkenil i alkinil; R1 je izabran od: [image] i [image] gdje je Rb nezavisno izabran u svakom slučaju iz grupe koju čine H, arilalkil, 5-6-člani heterociklil-C1-3 alkil, C1-6-alkil, C6-10 aril, C6-10 heteroaril, C3-6 cikloalkil, benzil, C1-3 alkilaril, C1-3alkilheteroaril, metil, etil, izopropil, butil, sek-butil, izobutil, metoksimetil, -(C1-6)alkil, 2-hidroksi 2-metilbutil, 2-hidroksi-2-metilpropil, 2-hidroksipropil, 1-(1-hidroksiciklopropil) metil, etilaminometil, piperidin-1-ilmetil, pirolidin-1-ilmetil, piridil, tienil, fenil, 1-naftil, nitril, -C(=O)OR5a, -C(=O)NR5aRa i -C(=O)R5a; gdje je Rc jedan ili više supstituenata izabranih od H, metil, izopropil, terc-butil, bromo, fluoro i hidroksil; svako R3 i R4 nezavisno su izabrani iz grupe koju čine H, alkil, aril, heterociklil, arilalkil, cikloalkil i cikloalkilalkil; alternativno R3 i R4, zajedno sa atomom za koji su vezani, formiraju 3-6 –člani prsten; R5 je nezavisno izabran u svakom slučaju iz grupe koju čine H, alkil, haloalkil, heterociklilalkil, cikloalkilalkil, aril i heterociklil; R5a je nezavisno izabran u svakom sluičaju od H, alkil, haloalkil, arilalkil aminoalkil, heterociklilalkil, cikloalkilalkil, aril, heterociklil, alkenil, alkinil i cikloalkil; R7 je izabran iz grupe koju čine H, halo, cijano i alkil; R8* je jedan ili više supstituenata nezavisno izabranih u svakom slučaju od OC(=O)NRaR5, -NRaC(=O)OR5 i -NRaC(=O)-R5; p je 0, 1, 2 ili 3; i gdje je svaka alkil, aril, heteroaril, cikloalkil, alkenil, alkinil, heterociklil i alkoksi grupa od bilo kojeg R, R1, R3, R4, R5, R7, R8* i Ra izborno nezavisno supstituirana sa jednom ili više grupa nezavisno izabranih u svakom slučaju od halo, okso, -NRaR5, -OR5a, -CO2R5, -C(=O)R5, (C1-C6)alkilamino, -NH-N=NH, (C1-C6)alkil, (C1-C6)alkinil, (C3-C6)cikloalkil, (C1-C6)haloalkil, di(C1-C6)alkilamino, (C1-C6)alkilamino-(C1-C6)alkil, (C1-C6)hidroksialkilamino, (C1-C6)alkilamino-(C1-C6)alkilamino, fenil, heterociklik, heteroaril, -(CR3R4)palkil-S(=O)-alkil i -(CR3R4)palkil-S(O)2-alkil, pri čemu je svaki alkenil naveden ovdje u prethodnom tekstu – linearni ili razgranati radikal od dva do dvanaest atoma ugljika koji ima najmanje jednu ugljik-ugljik dvogubu vezu i pri čemu je svaki alkinil naveden ovdje u prethodnom tekstu linearni ili razgranati radikal od dva do dvanaest atoma ugljika koji ima najmanje jednu ugljik-ugljik trogubu vezu.
2. Spoj prema patentnom zahtjevu 1, naznačen time što, W je supstituiran ili nesupstituiran fenil; i njegove farmaceutski prihvatljive soli.
3. Spoj prema patentnom zahtjevu 1, naznačen time što, W je supstituiran ili nesupstituiran piridil; i njegove farmaceutski prihvatljive soli.
4. Spoj prema patentnom zahtjevu 1, naznačen time što, Y je izabran od -NHC(=O)- i -NHC(=O)-(CH2)p-; i gdje je p jednako 0 ili 1; i njegove farmaceutski prihvatljive soli.
5. Spoj prema patentnom zahtjevu 1, naznačen time što, Y je -NHC(=O)-; i njegove farmaceutski prihvatljive soli.
6. Spoj prema patentnom zahtjevu 1, naznačen time što, p je 0; i njegove farmaceutski prihvatljive soli.
7. Spoj i njegove farmaceutski prihvatljive soli i solvati izabrani od slijedećih N-(3-fluoro-4-(2-(3-metil-1,2,4-oksadiazol-5-il)tieno[3,2-b]piridin-7-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-((2-(1-metil-1H-imidazol-5-il)tieno[3,2-b]piridin-7-il)oksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-((2-(1-metil-1H-imidazol-5-il)tieno[3,2-b]piridin-7-il)oksi)fenil)-1-((2R)-2-hidroksipropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(7H-pirolo[2,3-d]pirimidin-4-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(1H-pirolo[2,3-b]piridin-4-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; Metil(6-((4-(((1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-il)karbonil)amino)fenil)oksi)-1H-benzimidazol-2-il)karbamat; N-(4-(2-(azetidin-1-karbonil)tieno[3,2-b]piridin-7-iloksi)-3-fluorofenil)-5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamid; 7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)-N-metiltieno[3,2-b]piridin-2-karboksamid; N-(3-fluoro-4-(2-(1-metilpiperazin-4-karbonil)tieno[3,2-b]piridin-7-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(2-(dimetilamino)etil)-7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)tieno[3,2-b]piridin-2-karboksamid; N-(4-(2-(3-(dimetilamino)pirolidin-1-karbonil)tieno[3,2-b]piridin-7-iloksi)-3-fluorofenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; 7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)-N,N-dimetiltieno[3,2-b]piridin-2-karboksamid; 7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)tieno[3,2-b]piridin-2-karboksamid; N-(2-(dimetilamino)etil)-7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)-N-metiltieno[3,2-b]piridin-2-karboksamid; 7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)-N-(2-metoksietil)tieno[3,2-b]piridin-2-karboksamid; N-(4-(2-(azetidin-1-karbonil)tieno[3,2-b]piridin-7-iloksi)-3-fluorofenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-ciklopropil-7-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)tieno[3,2-b]piridin-2-karboksamid 7-(2-fluoro-4-(5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamido) fenoksi)tieno[3,2-b]piridin-2-karboksamid; N-(3-fluoro-4-(6-(pirolidin-1-karboksamido)pirimidin-4-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(6-(pirolidin-1-karboksamido)pirimidin-4-iloksi)fenil)-5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(6-(4-(1,5-dimetil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)-2-fluorofenoksi)pirimidin-4-il)morfolin-4-karboksamid; N-(6-(2-fluoro-4-(5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)pirimidin-4-il)morfolin-4-karboksamid; N-(6-(2-fluoro-4-(5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)pirimidin-4-il)piperidin-1-karboksamid; N-(6-(2-fluoro-4-(5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)pirimidin-4-il)-4-metilpiperazine-1-karboksamid; (R)-N-(4-(6-(3-(dimetilamino)pirolidin-1-karboksamido)pirimidin-4-iloksi)-3-fluorofenil)-5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamid; (R)-N-(4-(6-aminopirimidin-4-iloksi)-3-fluorofenil)-1-(2-hidroksipropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(2-(pirolidin-1-karboksamido)piridin-4-iloksi)fenil)-1,5-dimetil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(4-(4-(1,5-dimetil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)-2-fluorofenoksi)piridin-2-il)piperidin-1-karboksamid; (R)-N-(4-(2-(3-(dimetilamino)pirolidin-1-karboksamido)piridin-4-iloksi)-3-fluorofenil)-1,5-dimetil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(2-(pirolidin-1-karboksamido)piridin-4-iloksi)fenil)-1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(3-fluoro-4-(2-(pirolidin-1-karboksamido)piridin-4-iloksi)fenil)-5-metil-3-okso-2-fenil-1-propil-2,3-dihidro-1H-pirazol-4-karboksamid; N-(4-(4-(1,5-dimetil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)-2-fluorofenoksi) piridin-2-il)morfolin-4-karboksamid; N-(4-(2-fluoro-4-(1-(2-hidroksi-2-metilpropil)-5-metil-3-okso-2-fenil-2,3-dihidro-1H-pirazol-4-karboksamido)fenoksi)piridin-2-il)piperidin-1-karboksamid; N-(3-fluoro-4-(2-(pirolidin-1-karboksamido)piridin-4-iloksi)fenil)-3-okso-2-fenil-2,3-dihidropiridazin-4-karboksamid; [image] [image] i [image]
8. Farmaceutska kompozicija koja sadrži farmaceutski prihvatljiv nosač i spoj prema bilo kojem od patentnih zahtjeva 1-7.
9. Spoj prema bilo kojem od patentnih zahtjeva 1-7 za uporabu u postupku za liječenje kancera kod subjekta.
10. Spoj za uporabu prema patentnom zahtjevu 9 koji sačinjava kombinaciju sa spojem koji je izabran od sredstava tipa antibiotika, alkilirajućih sredstava, antimetabolita, hormonalnih sredstava, imunoloških sredstava, sredstava tipa interferona i raznih sredstava.
11. Spoj prema bilo kojem od patentnih zahtjeva 1-7 za uporabu u smanjenju veličine tumora kod subjekta.
12. Spoj prema bilo kojem od patentnih zahtjeva 1-7 za uporabu u liječenju poremećaja posredovanih preko HGF kod subjekta.
13. Spoj prema bilo kojem od patentnih zahtjeva 1-7 za uporabu u smanjenju metastaze kod tumora kod subjekta.
14. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-7 za pripremu lijeka za liječenje kancera kod subjekta.
15. Uporaba prema patentnom zahtjevu 14, naznačena time što lijek dalje sadrži spoj koji je izabran od sredstava tipa antibiotika, alkilirajućih sredstava, antimetabolita, hormonalnih sredstava, imunoloških sredstava, sredstava tipa interferona i raznih sredstava.
16. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-7 za pripremu lijeka za smanjenje veličine tumora kod subjekta.
17. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-7 za pripremu lijeka za liječenje poremećaja posredovanih preko HGF kod subjekta.
18. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1-7 za pripremu lijeka za smanjenje metastaze kod tumora kod subjekta.
HRP20121069TT 2005-04-27 2006-04-27 Supstituirani derivati amida kao inhibitori protein kinaze HRP20121069T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67580505P 2005-04-27 2005-04-27
PCT/US2006/016344 WO2006116713A1 (en) 2005-04-27 2006-04-27 Substituted amide derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20121069T1 true HRP20121069T1 (hr) 2013-01-31

Family

ID=36617399

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20121069TT HRP20121069T1 (hr) 2005-04-27 2006-04-27 Supstituirani derivati amida kao inhibitori protein kinaze

Country Status (33)

Country Link
US (3) US7858623B2 (hr)
EP (1) EP1881976B1 (hr)
JP (1) JP5463033B2 (hr)
KR (1) KR20080004617A (hr)
CN (1) CN101248059A (hr)
AR (1) AR054262A1 (hr)
AU (1) AU2006239216B2 (hr)
BR (1) BRPI0608097A2 (hr)
CA (1) CA2605680C (hr)
CR (1) CR9475A (hr)
CY (1) CY1113324T1 (hr)
DK (1) DK1881976T3 (hr)
EA (1) EA013231B1 (hr)
ES (1) ES2396219T3 (hr)
GT (1) GT200600181A (hr)
HN (1) HN2006016313A (hr)
HR (1) HRP20121069T1 (hr)
IL (1) IL186526A (hr)
JO (1) JO2787B1 (hr)
MX (1) MX2007013216A (hr)
MY (1) MY177111A (hr)
NO (1) NO20076093L (hr)
NZ (1) NZ562595A (hr)
PE (1) PE20061436A1 (hr)
PL (1) PL1881976T3 (hr)
PT (1) PT1881976E (hr)
RS (1) RS52596B (hr)
SI (1) SI1881976T1 (hr)
TW (1) TWI378094B (hr)
UA (1) UA93375C2 (hr)
UY (1) UY29503A1 (hr)
WO (1) WO2006116713A1 (hr)
ZA (1) ZA200708775B (hr)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CA2553423C (en) * 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
KR101257343B1 (ko) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
EP1928454B1 (en) 2005-05-10 2014-09-24 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
NZ563774A (en) 2005-05-20 2010-04-30 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
AR055206A1 (es) * 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
CA2648284C (en) 2006-04-07 2016-08-16 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US20090306103A1 (en) * 2006-05-19 2009-12-10 Stephen Boyer Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2008035209A2 (en) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
HRP20130626T1 (en) 2006-11-08 2013-08-31 Bristol-Myers Squibb Company Pyridinone compounds
US8338455B2 (en) 2006-12-20 2012-12-25 Amgen Inc. Compounds and methods of use
US7915287B2 (en) 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
JP5343082B2 (ja) * 2007-10-29 2013-11-13 アムジエン・インコーポレーテツド ベンゾモルホリン誘導体および使用方法
KR20100096131A (ko) 2007-11-06 2010-09-01 아스트라제네카 아베 특정 2-피라지논 유도체 및 호중구 엘라스타제의 억제제로서의 이의 용도
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
DK2235002T3 (da) 2008-01-23 2013-03-11 Bristol Myers Squibb Co 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
CN102161663B (zh) * 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
PT2384326E (pt) 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
AU2009298888A1 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
MX2011003363A (es) * 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
EP2373636A4 (en) * 2008-12-05 2012-10-17 Merck Sharp & Dohme INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
AU2010271105C1 (en) 2009-01-12 2014-08-21 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
RU2011142597A (ru) 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
JP2012525336A (ja) * 2009-04-27 2012-10-22 エラン ファーマシューティカルズ，インコーポレイテッド α−４インテグリンのピリジノンアンタゴニスト
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
BR112012004843A2 (pt) * 2009-09-03 2019-09-24 Allergan Inc compostos como moduladores de tirosina cinase
CN102574789B (zh) * 2009-09-21 2014-12-10 凯莫森特里克斯股份有限公司 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂
KR20120099639A (ko) 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
WO2011080341A1 (en) 2010-01-04 2011-07-07 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
CN102212062B (zh) * 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
AU2011241420B2 (en) * 2010-04-16 2015-04-16 Methylgene Inc. Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
EP2594566A4 (en) * 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
SG190735A1 (en) 2011-02-28 2013-07-31 Calitor Sciences Llc Substituted quinoline compounds and methods of use
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA2844588A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
AU2012296543B2 (en) 2011-08-16 2016-08-11 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
RU2605289C2 (ru) 2011-08-30 2016-12-20 Астекс Фармасьютикалз, Инк. Состав, набор и фармацевтическая композиция, содержащие производные децитабина, их получение и применение
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
ES2774972T3 (es) 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Tratamiento de enfermedades oculares
HK1202450A1 (zh) * 2011-11-22 2015-10-02 Deciphera Pharmaceuticals, Llc. 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
CN103420986A (zh) * 2012-05-18 2013-12-04 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
SG11201408254UA (en) * 2012-06-26 2015-01-29 Bayer Pharma AG N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
CN104507930B (zh) * 2012-06-29 2017-10-10 贝达药业股份有限公司 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103565653B (zh) * 2012-07-16 2017-01-25 广东东阳光药业有限公司 取代的吡唑酮化合物及其使用方法和用途
MX2015001424A (es) 2012-07-28 2016-03-09 Calitor Sciences Llc Compuestos pirazolona sustituidos y metodos de uso.
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
TWI570116B (zh) * 2012-08-03 2017-02-11 習寧 取代的吡唑酮化合物及其使用方法
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102057366B1 (ko) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 치환된 벤젠 화합물
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AR094707A1 (es) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX371382B (es) 2013-03-15 2020-01-28 Aerpio Therapeutics Inc Composiciones, formulaciones y metodos para tratar enfermedades oculares.
DK3003315T3 (en) * 2013-06-06 2018-04-16 Lead Discovery Center Gmbh Quinoline inhibitor of the macrophage stimulating 1 receptor MST1R
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ES2960953T3 (es) 2013-10-16 2024-03-07 Epizyme Inc Forma de sal de clorhidrato para la inhibición de EZH2
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN104974162B (zh) * 2014-04-09 2018-09-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
EP3134088B1 (en) * 2014-04-22 2019-04-10 Calitor Sciences, LLC Bicylcic pyrazolone compounds and methods of use
JP6708130B2 (ja) * 2014-12-25 2020-06-10 小野薬品工業株式会社 キノリン誘導体
CA2980652C (en) 2015-04-14 2021-04-27 Qurient Co., Ltd. Quinoline derivatives as tam rtk inhibitors
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
WO2017012539A1 (en) * 2015-07-20 2017-01-26 Betta Pharmaceuticals Co.,Ltd Crystalline form of fused pyridine derivative's maleate and uses thereof
CN106632254B (zh) * 2015-11-02 2019-03-01 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
CN106632253B (zh) * 2015-11-02 2019-03-22 广东东阳光药业有限公司 一种取代的喹啉化合物的晶型及其药物组合物和用途
US9920033B2 (en) * 2015-11-14 2018-03-20 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
US9695150B2 (en) * 2015-11-14 2017-07-04 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
TWI836679B (zh) 2016-02-05 2024-03-21 美商戴納立製藥公司 化合物、組合物及方法
CN107286140A (zh) * 2016-04-12 2017-10-24 上海医药工业研究院 取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
WO2017198196A1 (zh) * 2016-05-18 2017-11-23 王子厚 具有抗肿瘤活性的喹啉衍生物
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
RS63203B1 (sr) 2016-12-09 2022-06-30 Denali Therapeutics Inc Jedinjenja korisna kao inhibitori ripk1
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CN119707932A (zh) 2017-01-26 2025-03-28 小野药品工业株式会社 喹啉衍生物的乙磺酸盐
KR102603153B1 (ko) 2017-04-27 2023-11-15 아스트라제네카 아베 C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도
WO2019016071A1 (en) 2017-07-18 2019-01-24 Bayer Pharma Aktiengesellschaft SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
CN111182908A (zh) 2017-08-03 2020-05-19 大塚制药株式会社 药物化合物及其纯化方法
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungidal heterocyclic compounds
BR112020004356A2 (pt) 2017-09-08 2020-12-01 Pi Industries Ltd. novos compostos heterocíclicos fungicidas
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN110041316B (zh) * 2018-01-17 2022-04-19 药捷安康(南京)科技股份有限公司 Tam家族激酶/和csf1r激酶抑制剂及其用途
ES2980476T3 (es) 2018-03-08 2024-10-01 Wellmarker Bio Co Ltd Derivados de tienopiridina y composición farmacéutica que los contiene
EP3768269B1 (en) * 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
CN110372666B (zh) * 2018-04-13 2022-11-08 华东理工大学 喹唑啉类化合物作为egfr三突变抑制剂及其应用
CN110511218A (zh) * 2018-05-21 2019-11-29 中国科学院上海药物研究所 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
CN111518016B (zh) * 2018-06-01 2022-02-25 厦门宝太生物科技股份有限公司 一种csf1r抑制剂中间体及其制备方法
CN108727386A (zh) * 2018-07-16 2018-11-02 广州医科大学 一种吡唑并嘧啶类化合物及其制备方法和用途
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
US20220047603A1 (en) 2018-12-11 2022-02-17 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CN111303024B (zh) 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
EP4005637A4 (en) * 2019-07-29 2023-07-19 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
CN114391012B (zh) * 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
FI4010330T3 (fi) * 2019-08-08 2025-12-17 Hirundo Biosciences Kinoliinijohdannaisia proteiinikinaasiestäjinä
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CN114787144A (zh) * 2019-09-26 2022-07-22 埃克塞里艾克西斯公司 吡啶酮化合物及用于调节蛋白激酶的方法
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN113121429B (zh) * 2020-01-15 2024-04-26 鲁南制药集团股份有限公司 一种c-Met激酶抑制剂及其制备方法和应用
US20230151003A1 (en) * 2020-02-24 2023-05-18 Exelixis, Inc. Compounds and methods of use
CN111440174B (zh) * 2020-04-02 2021-07-09 广州医科大学 一种吡啶酰胺类化合物及其制备方法与应用
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors
KR102868758B1 (ko) 2021-04-13 2025-10-14 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
TWI822140B (zh) * 2021-06-24 2023-11-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
CN113999205B (zh) * 2021-12-13 2023-09-15 辽宁大学 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用
CN119212987A (zh) 2021-12-16 2024-12-27 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物
KR20240132504A (ko) 2022-01-12 2024-09-03 데날리 테라퓨틱스 인크. (s)-5-벤질-n-(5-메틸-4-옥소-2,3,4,5-테트라하이드로피리도 [3,2-b][1,4]옥사제핀-3-일)-4h-1,2,4-트리아졸-3-카복사미드의 결정질 형태
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN116283920B (zh) * 2023-03-31 2024-04-16 贵州医科大学 2,4-二取代吡啶类化合物及其应用
CN117126142B (zh) * 2023-08-30 2026-02-10 遵义医科大学珠海校区 杂环类egfr突变抑制剂及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH08193070A (ja) * 1995-01-11 1996-07-30 Mitsubishi Chem Corp ２−イミダゾリジノン誘導体及びそれを有効成分とする除草剤、並びにその製造中間体
AU4547396A (en) 1995-01-31 1996-08-21 Zenyaku Kogyo Kabushiki Kaisha Thioquinoline derivatives
GB9505702D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd Fungicidal compounds
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
BR9607089A (pt) 1995-11-14 1997-11-11 Pharmacia & Upjohn Spa Compostos de pirimidina condensada biciclica composição farmacéutica utilização e produtos que contém os mesmos e processo para a preparação desses compostos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
IL131475A0 (en) 1997-02-19 2001-01-28 Berlex Lab N-heterocyclic derivatives as nos inhibitors
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2328973A1 (en) 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
IL139641A0 (en) 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
IL144461A0 (en) 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
DE60017389T2 (de) 1999-04-12 2006-03-02 Aventis Pharma Ltd., West Malling Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
CN1391561A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 喹唑啉化合物和含有喹唑啉化合物的药物组合物
EP1263755A2 (en) 2000-03-17 2002-12-11 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
IL151018A0 (en) 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001268545A1 (en) 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
AU2002250394A1 (en) 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
ATE383858T1 (de) 2001-06-06 2008-02-15 Aventis Pharma Ltd Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen
US7425564B2 (en) 2001-06-22 2008-09-16 Kirin Beer Kabushiki Kaisha Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
AU2001271166A1 (en) 2001-07-05 2002-01-08 Telefonaktiebolaget Lm Ericsson (Publ) Detrimental latch-up avoidance
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ATE423104T1 (de) 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR101093345B1 (ko) 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
WO2003082272A1 (en) 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
EP1548008A4 (en) 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
AU2003285952A1 (en) 2002-10-21 2004-05-13 Irm Llc Pyrrolidones with anti-hiv activity
AR041992A1 (es) 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
AU2004218456A1 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists.
AU2004221812B2 (en) 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
AU2004255566B2 (en) 2003-07-07 2010-07-08 Merk Patent Gmbh Malonamide derivatives
BRPI0414011A (pt) 2003-08-29 2006-10-24 Pfizer naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7523317B2 (en) 2004-04-29 2009-04-21 International Business Machines Corporation Computer grid access management system
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors

Also Published As

Publication number Publication date
JP2008539275A (ja) 2008-11-13
KR20080004617A (ko) 2008-01-09
EP1881976B1 (en) 2012-10-17
CA2605680A1 (en) 2006-11-02
UY29503A1 (es) 2006-11-30
PT1881976E (pt) 2012-11-21
GT200600181A (es) 2007-05-08
AR054262A1 (es) 2007-06-13
ZA200708775B (en) 2008-06-25
JP5463033B2 (ja) 2014-04-09
ES2396219T3 (es) 2013-02-20
CY1113324T1 (el) 2016-06-22
PL1881976T3 (pl) 2013-03-29
CA2605680C (en) 2012-10-16
SI1881976T1 (sl) 2013-01-31
NO20076093L (no) 2008-01-25
CN101248059A (zh) 2008-08-20
MX2007013216A (es) 2007-12-12
US20120070413A1 (en) 2012-03-22
JO2787B1 (en) 2014-03-15
TW200716596A (en) 2007-05-01
US20080312232A1 (en) 2008-12-18
BRPI0608097A2 (pt) 2009-11-10
IL186526A (en) 2012-10-31
UA93375C2 (ru) 2011-02-10
TWI378094B (en) 2012-12-01
US20110118252A1 (en) 2011-05-19
US7858623B2 (en) 2010-12-28
HK1116161A1 (en) 2008-12-19
HN2006016313A (es) 2010-06-08
RS52596B (sr) 2013-04-30
IL186526A0 (en) 2008-01-20
AU2006239216A1 (en) 2006-11-02
PE20061436A1 (es) 2007-02-08
MY177111A (en) 2020-09-07
NZ562595A (en) 2011-02-25
EA200702339A1 (ru) 2008-04-28
US8685983B2 (en) 2014-04-01
CR9475A (es) 2008-03-07
WO2006116713A1 (en) 2006-11-02
AU2006239216B2 (en) 2012-11-29
EP1881976A1 (en) 2008-01-30
DK1881976T3 (da) 2013-02-04
US8088794B2 (en) 2012-01-03
EA013231B1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
ES2574154T3 (es) Compuestos de quinolina adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-HT6
ME02409B (me) Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
HRP20171999T1 (hr) Novi derivati aminopirimidina
RU2009113612A (ru) Ацетамидные производные хиназолинона и изохинолинона
PH12018501788A1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JP2015523390A5 (hr)
RU2012120288A (ru) Новые производные нафтиридина и их применение в качестве ингибиторов киназы
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
RU2008126807A (ru) Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов
CA2515343A1 (en) Antiparasitic terpene alkaloids
HRP20160002T1 (hr) Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
JP2009529047A5 (hr)
HRP20160824T2 (hr) Derivati benzotiofena supstituirani piperazinom kao antipsihotički agensi
JP2015528018A5 (hr)
RU2008141239A (ru) Соединения тетрагидропиридотиенопиримидина и способы их применения
NZ602948A (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
RU2014109747A (ru) Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
RU2012125152A (ru) Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований
HRP20110759T1 (hr) Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7
RU2018143284A (ru) Некоторые ингибиторы протеинкиназы